Archive for November 16, 2016

Effect of chlorhexidine bathing in preventing infections and reducing skin burden and environmental contamination: A review of the literature.

Am J Infect Control. 2016 May 2;44(5 Suppl):e17-21.

Donskey CJ1, Deshpande A2.

Author information

1Geriatric Research, Education, and Clinical Center, Cleveland Veterans Affairs Medical Center, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH. Electronic address: curtisd123@yahoo.com  

2Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH; Medicine Institute Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH.

Abstract

Chlorhexidine bathing is effective in reducing levels of pathogens on skin.

In this review, we examine the evidence that chlorhexidine bathing can prevent colonization and infection with health care-associated pathogens and reduce dissemination to the environment and the hands of personnel.

The importance of education and monitoring of compliance with bathing procedures is emphasized in order to optimize chlorhexidine bathing in clinical practice.

PDF

http://www.ajicjournal.org/article/S0196-6553(16)00200-5/pdf

Advertisements

November 16, 2016 at 12:51 pm

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections.

Infect Drug Resist. 2016 Apr 15;9:47-58.

Gonzalez-Ruiz A1, Seaton RA2, Hamed K3.

Author information

1Darent Valley Hospital, Dartford, UK.

2Queen Elizabeth University Hospital, Glasgow, UK.

3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Abstract

Infections caused by Gram-positive pathogens remain a major public health burden and are associated with high morbidity and mortality.

Increasing rates of infection with Gram-positive bacteria and the emergence of resistance to commonly used antibiotics have led to the need for novel antibiotics.

Daptomycin, a cyclic lipopeptide with rapid bactericidal activity against a wide range of Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, has been shown to be effective and has a good safety profile for the approved indications of complicated skin and soft tissue infections (4 mg/kg/day), right-sided infective endocarditis caused by S. aureus, and bacteremia associated with complicated skin and soft tissue infections or right-sided infective endocarditis (6 mg/kg/day).

Based on its pharmacokinetic profile and concentration-dependent bactericidal activity, high-dose (>6 mg/kg/day) daptomycin is considered an important treatment option in the management of various difficult-to-treat Gram-positive infections.

Although daptomycin resistance has been documented, it remains uncommon despite the increasing use of daptomycin. To enhance activity and to minimize resistance, daptomycin in combination with other antibiotics has also been explored and found to be beneficial in certain severe infections.

The availability of daptomycin via a 2-minute intravenous bolus facilitates its outpatient administration, providing an opportunity to reduce risk of health care-associated infections, improve patient satisfaction, and minimize health care costs.

Daptomycin, not currently approved for use in the pediatric population, has been shown to be widely used for treating Gram-positive infections in children.

PDF

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846043/pdf/idr-9-047.pdf

November 16, 2016 at 8:20 am


Calendar

November 2016
M T W T F S S
« Oct   Dec »
 123456
78910111213
14151617181920
21222324252627
282930  

Posts by Month

Posts by Category